Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021203044 - HIGH-THROUGHPUT ASSAY FOR CIRCULATING ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Publication Number WO/2021/203044
Publication Date 07.10.2021
International Application No. PCT/US2021/025640
International Filing Date 02.04.2021
IPC
C07K 14/005 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C12N 7/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
CPC
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
G01N 2333/165
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/54313
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
54313the carrier being characterised by its particulate form
G01N 33/56983
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
56983Viruses
Applicants
  • ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]/[US]
  • THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS [US]/[US]
Inventors
  • ZOLLA-PAZNER, Susan
  • KRAMMER, Florian
  • SIMON, Viviana
  • WEISS, Svenja
Agents
  • TISCHNER, Tate, L.
  • CHILDS, Carissa, R.
  • O'GARA, Megan, T.
  • GOLDMAN, Michael, L.
Priority Data
63/005,19103.04.2020US
63/029,23222.05.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HIGH-THROUGHPUT ASSAY FOR CIRCULATING ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
(FR) DOSAGE À HAUT RENDEMENT POUR LA CIRCULATION D'ANTICORPS CONTRE LE CORONAVIRUS 2 DU SYNDROME RESPIRATOIRE AIGU SÉVÈRE
Abstract
(EN) The present application relates to a high-throughput assay for circulating antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), including beads comprising a recombinant SARS-CoV-2 protein or epitope thereof; a kit comprising a population of beads, where each bead comprises a recombinant SARS-CoV-2 protein or epitope thereof and a detection reagent; a method for detecting the presence of antibodies in a subject that bind to a protein of SARS-CoV-2; and a method for assessing the efficacy of a vaccine which alters anti-SARS-CoV-2 protein antibody levels in a subject.
(FR) La présente invention concerne un dosage à haut rendement pour la circulation d'anticorps contre le coronavirus 2 du syndrome respiratoire aigu sévère (SARS-CoV-2), y compris des billes comprenant une protéine de SARS-CoV-2 recombinante ou un épitope de celle-ci; un kit comprenant une population de billes, chaque bille comprenant une protéine de SARS-CoV-2 recombinante ou un épitope de celle-ci et un réactif de détection; une méthode de détection chez un sujet de la présence d'anticorps qui se lient à une protéine du SARS-CoV-2; et une méthode d'évaluation de l'efficacité d'un vaccin qui modifie les taux d'anticorps protéiques anti-SARS-CoV-2 chez un sujet.
Latest bibliographic data on file with the International Bureau